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Abstract 
Background: The small-molecule nutlin-3 was found to be an effective therapeutic compound 
and p53 activator, and acts as a murine double minute 2 antagonist, although these findings 
need to be clinically confirmed. The essential components of the bone marrow include 
mesenchymal stem cells (MSCs), which play a key role in protecting, regenerating, and 
proliferating hematopoietic stem cells (HSCs). This feature is vital for HSC after exposure to 
myelotoxic anticancer agents; nevertheless, the effects of nutlin-3 on MSCs remain to be 
disclosed. The present research study was conducted to examine the antiproliferative and 
proapoptotic effectiveness of nutlin-3 in bone marrow MSCs (BMSCs). Materials and 
Methods: Human-derived BMSCs were cultured for different durations, that is, 24, 48, and 72 
hours, and treated using various concentrations of nutlin-3, including 5, 10, 25, 50, and 100 
μΜ. To investigate the effect of nutlin-3 on the apoptosis, cell vitality and proliferation in 
BMSCs, the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), thiazolyl 
blue tetrazolium bromide, propidium iodide (PI) and annexin V assay, as well as real-time 
polymerase chain reaction, were used. Results: BMSCs viability significantly decreased (P 
<.05) in the cells treated at concentrations of 50 and 100 μM for 24 hours and concentrations 
of 25, 50, and 100 μM for 48 hours and at all concentrations for 72 hours. The apoptosis of 
BMSCs (TUNEL positive) was significantly more visible at concentrations of 25 and 50 μM 
compared with that in the controls (P <.05), while this increased through dose-dependent 
processes. Annexin V/PI staining revealed negligible dose-dependent increases in all the 
apoptotic cells after 72 hours of incubation, and this apoptosis elevation was significant at 25 
and 50 μM (P <.05). Conclusion: Resistance to nutlin-3 was observed in human bone marrow–
derived MSCs; nevertheless, further clinical data are required to be obtained with long-duration 
exposure to confirm the present findings. 
 
